RMD Analyst Estimates: Price Targets, Revenue, Net Income, and EBIT Forecast - Resmed Inc - Alpha Spread

First Time Loading...

Watchlist Manager

Watchlist

Price: 218.15 USD 1.46%

Updated:

Section:

Wall Street
Price Targets

Wall Street analysts forecast RMD stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RMD is 216.59 USD with a low forecast of 181.8 USD and a high forecast of 249.9 USD.

RMD Lowest Forecast

Wall Street Target

RMD Average Forecast

Wall Street Target

RMD Highest Forecast

Wall Street Target

17% Downside

1% Downside

15% Upside

The latest public price target was made on Apr 10, 2024 by Craig Wong-Pan from RBC Capital , who expects RMD stock to drop by 14% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst	Price Target	Date	Article
Craig Wong-Pan RBC Capital	187 USD Downside 14%	3 weeks ago Apr 10, 2024	ResMed (RMD) PT Raised to $187 at RBC Capital StreetInsider
Mike Matson Stifel Nicolaus	224 USD Upside 3%	1 month ago Apr 1, 2024	ResMed (RMD) PT Raised to $224 at Stifel StreetInsider
Suraj Kalia Oppenheimer	175 USD Downside 20%	6 months ago Oct 27, 2023	How Sleep Device Player ResMed Is Gaining Philips' Market Share In Flow Generator Market - Analysts Weigh In Benzinga
Mike Matson Needham	180 USD Downside 17%	7 months ago Sep 6, 2023	Needham & Company Upgrades ResMed (RMD) to Buy StreetInsider

Price Target	187 USD
Upside/Downside	14%

Price Target	224 USD
Upside/Downside	3%

Price Target	175 USD
Upside/Downside	20%

Price Target	180 USD
Upside/Downside	17%

Mehow Innovative Ltd

46% Upside

Inari Medical Inc

75% Upside

Metall Zug AG

60% Upside

LivaNova PLC

10% Upside

Mehow Innovative Ltd

46% Upside

Inari Medical Inc

75% Upside

Metall Zug AG

60% Upside

LivaNova PLC

10% Upside

Shockwave Medical Inc

2% Downside

Daiken Medical Co Ltd

62% Upside

Teleflex Inc

36% Upside

Rion Co Ltd

28% Upside

Revenue
Forecast

For the last 8 years the compound annual growth rate for Resmed Inc's revenue is 12%. The projected CAGR for the next 3 years is 8%.

12%

8%

-1%

What are analyst estimates?

Operating Income
Forecast

For the last 8 years the compound annual growth rate for Resmed Inc's operating income is 14%. The projected CAGR for the next 3 years is 13%.

14%

13%

-5%

What are analyst estimates?

Net Income
Forecast

For the last 8 years the compound annual growth rate for Resmed Inc's net income is 12%. The projected CAGR for the next 3 years is 14%.

12%

14%

-11%

What are analyst estimates?

See Also

Relative Valuation

Wall Street Estimates

Profitability Analysis

Solvency Analysis

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

According to Wall Street analysts, the average 1-year price target for RMD is 216.59 USD with a low forecast of 181.8 USD and a high forecast of 249.9 USD.

For the last 8 years the compound annual growth rate for Resmed Inc's revenue is 12%. The projected CAGR for the next 3 years is 8%.

For the last 8 years the compound annual growth rate for Resmed Inc's operating income is 14%. The projected CAGR for the next 3 years is 13%.

For the last 8 years the compound annual growth rate for Resmed Inc's net income is 12%. The projected CAGR for the next 3 years is 14%.

Join more than 133,600+ value investors using Alpha Spread

Create a free account

or see our plans & pricing

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

What is Intrinsic Value? Help Center Contact Us

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.